[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658599":3},{"organization":4,"outcomesModule":7,"designInfo":46,"detailedDescription":48,"studyPopulation":49,"armGroups":50,"interventions":56,"overallOfficials":63,"centralContacts":71,"locations":79,"responsibleParty":311,"collaborators":314,"id":334,"slug":335,"hasResults":336,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":336,"sex":342,"minAge":343,"maxAge":45,"enrollmentInfo":344,"targetDuration":347,"studyType":348,"phases":45,"briefSummary":349,"conditions":350,"keywords":355,"overallStatus":82,"whyStopped":45,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":389},{"fullName":5,"class":6},"Azienda Ospedaliero-Universitaria Careggi","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":45},[9,13],{"measure":10,"description":11,"timeFrame":12},"All-cause mortality at 30 days","Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries.","30 days after diagnosis",{"measure":14,"description":15,"timeFrame":12},"PE-related mortality at 30 days","Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought.",[17,21,25,28,32,35,38,42],{"measure":18,"description":19,"timeFrame":20},"Hemodynamic decompensation","Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure \\\u003C90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event.","From diagnosis to hospital discharge or day 30, whichever comes first",{"measure":22,"description":23,"timeFrame":24},"All-cause mortality during follow-up","Proportion of patients who die from any cause during follow-up.","3 months, 12 months, and annually up to 5 years after diagnosis",{"measure":26,"description":27,"timeFrame":24},"PE-related mortality during follow-up","Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome.",{"measure":29,"description":30,"timeFrame":31},"Recurrent venous thromboembolism","Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted.","30 days, 3 months, 12 months, and annually up to 5 years after diagnosis",{"measure":33,"description":34,"timeFrame":31},"Major bleeding (ISTH criteria)","Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g\u002FdL (1.24 mmol\u002FL) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening according to Franco et al. (extracranial bleeding causing shock, or intracranial hemorrhage with Glasgow Coma Scale \\\u003C14).",{"measure":36,"description":37,"timeFrame":31},"Clinically relevant non-major bleeding","Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy.",{"measure":39,"description":40,"timeFrame":41},"Chronic thromboembolic pulmonary hypertension (CTEPH)","Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure \\>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance \\>2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC\u002FERS criteria). Diagnostic tests are performed only when clinically indicated.","From 3 months up to 5 years after diagnosis",{"measure":43,"description":44,"timeFrame":24},"Persistent functional limitation after pulmonary embolism (post-PE syndrome)","Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care.",null,{"allocation":45,"interventionModel":45,"interventionModelDescription":45,"primaryPurpose":45,"observationalModel":47,"timePerspective":6,"maskingInfo":45},"COHORT","BACKGROUND AND SCIENTIFIC RATIONALE\n\nPulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.\n\nSTUDY DESIGN AND COHORTS\n\nTime perspective: ambispective (retrospective and prospective cohorts, described below).\n\nPERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:\n\n1. Retrospective Phase (Historical Cohort): Includes consecutive adult patients diagnosed with acute PE from January 1, 2023, up to the date of local Ethics Committee approval at each participating site. Data are abstracted from medical records.\n2. Prospective Phase (Contemporary Cohort): Enrolls consecutive adult patients presenting with acute PE after local Ethics Committee approval, extending for a continuous enrollment period of 5 years. Data are collected during routine care.\n\nSTUDY SETTING AND CLINICAL CONTINUUM OF CARE\n\nData collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:\n\n* Baseline Presentation (T0): Captures pre-hospital emergency medical service (EMS) data (initial vital signs, cardiac arrest, point-of-care ultrasound \\[POCUS\\], pre-hospital anticoagulation or thrombolysis), ED arrival parameters, clinical symptoms, arterial blood gas analysis, admission laboratory biomarkers (high-sensitivity troponin, BNP\u002FNT-proBNP, lactate, D-dimer, renal function), electrocardiographic patterns, and multiorgan diagnostic imaging (CT pulmonary angiography \\[CTPA\\], complete echocardiography\u002FPOCUS, and compression venous ultrasound \\[CUS\\]).\n* Dynamic In-Hospital Reassessment (T1-T4): To capture real-world hemodynamic and respiratory trajectories, serial parameters documented during standard clinical monitoring are recorded across predefined temporal windows: T1 (3-6 hours), T2 (6-12 hours), T3 (12-24 hours), and T4 (24-48 hours). Parameters include serial vital signs, shock index, respiratory support modalities, serial lactate\u002Ftroponin kinetics, echocardiographic right ventricular function changes, and need for escalating hemodynamic or respiratory support (vasopressors, inotropes, non-invasive ventilation, mechanical ventilation, or ECMO).\n* Hospital Discharge \\& Complications: Documents in-hospital adverse events, need for rescue reperfusion, procedural complications, bleeding events, length of stay, and vital status at discharge.\n* Follow-up Surveillance: Thirty-day status is ascertained from clinical records. Follow-up then reflects routine care at 3 and 12 months and annually thereafter up to 5 years (in-person visit, telemedicine, telephone contact or review of clinical documentation), with regional mortality registries used to ascertain vital status when needed. Follow-up collects all-cause survival, cause of death, VTE recurrence, major and clinically relevant non-major bleeding, persistent functional limitation (modified Rankin Scale, exertional dyspnea, six-minute walk test when performed) and the development of chronic thromboembolic pulmonary hypertension (CTEPH).\n\nOUTCOMES\n\nOutcome definitions and time frames are reported in the Outcome Measures section.\n\nDATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE\n\nData collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).\n\n* Privacy and Data Segregation: Strict GDPR compliance is maintained. Patient data are pseudonymized at source by the local site investigator using site-specific Subject IDs. The decoding key linking the alphanumeric ID to personal identifiers is maintained exclusively at the local participating hospital under the responsibility of the local Principal Investigator.\n* Data Access Groups (DAGs): REDCap DAGs are enforced to compartmentalize site-level access, ensuring participating centers can exclusively view, enter, and edit their own center's records, with no unauthorized cross-center data visibility.\n* Quality Assurance: The eCRF includes built-in validation rules (range and logic checks). The coordinating center performs regular central monitoring for inconsistencies, outliers and missing data, and discrepancies are resolved with each center through a formal query process. The Steering Committee reviews enrollment, data quality and protocol adherence every 6 months.\n* Regulatory Framework: Protocol version 2.0 (7 May 2026) received a favourable opinion from the Comitato Etico Regione Toscana - Area Vasta Centro (CEAVC, register no. 30742\\_oss, meeting of 9 June 2026) for the sites of Azienda Ospedaliero-Universitaria Careggi and Azienda USL Toscana Centro. Participation of other national and international centers is subject to approval of a protocol amendment and of the competent local ethics committees. The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles and applicable privacy regulations (including Article 110-bis of the Italian Privacy Code).","Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.",[51],{"label":52,"type":45,"description":53,"interventionNames":54},"Adults with acute pulmonary embolism","Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care).",[55],"Other: Routine clinical care (no study intervention)",[57],{"type":6,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"Routine clinical care (no study intervention)","Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.",[52],[62],"Routine Clinical Practice, Usual Care",[64,68],{"name":65,"affiliation":66,"role":67},"Simone Vanni, MD, PhD","Azienda Ospedaliero-Universitaria Careggi \u002F University of Florence","PRINCIPAL_INVESTIGATOR",{"name":69,"affiliation":66,"role":70},"Matteo Gabriele Monda, MD","STUDY_DIRECTOR",[72,76],{"name":65,"role":73,"phone":74,"phoneExt":45,"email":75},"CONTACT","+393666904459","simone.vanni@unifi.it",{"name":69,"role":73,"phone":77,"phoneExt":45,"email":78},"+393209433394","matteogabriele.monda@gmail.com",[80,99,113,127,141,152,163,177,191,205,220,235,250,264,279,295],{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro","RECRUITING","Bagno a Ripoli","Tuscany","50012","Italy","IT",{"type":89,"coordinates":90},"Point",[91,92],11.32252,43.75115,{"lat":92,"lon":91},[95],{"name":96,"role":73,"phone":97,"phoneExt":45,"email":98},"Germana Ruggiano, MD","+39 055 69361","germana.ruggiano@uslcentro.toscana.it",{"facility":100,"status":82,"city":101,"state":84,"zip":102,"country":86,"countryCode":87,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Nuovo Ospedale del Mugello - Azienda USL Toscana Centro","Borgo San Lorenzo","50032",{"type":89,"coordinates":104},[105,106],11.38561,43.95548,{"lat":106,"lon":105},[109],{"name":110,"role":73,"phone":111,"phoneExt":45,"email":112},"Leonardo Delli, MD","+39 055 84511","leonardo.delli@uslcentro.toscana.it",{"facility":114,"status":82,"city":115,"state":84,"zip":116,"country":86,"countryCode":87,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Ospedale San Giuseppe - Azienda USL Toscana Centro","Empoli","50053",{"type":89,"coordinates":118},[119,120],10.94758,43.71795,{"lat":120,"lon":119},[123],{"name":124,"role":73,"phone":125,"phoneExt":45,"email":126},"Paola Bartalucci, MD","+39 0571 7051","paola.bartalucci@uslcentro.toscana.it",{"facility":128,"status":82,"city":129,"state":84,"zip":130,"country":86,"countryCode":87,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Ospedale Santa Maria Nuova - Azienda USL Toscana Centro","Florence","50122",{"type":89,"coordinates":132},[133,134],11.24626,43.77925,{"lat":134,"lon":133},[137],{"name":138,"role":73,"phone":139,"phoneExt":45,"email":140},"Michele Lanigra, MD","+39 055 69381","michele.lanigra@uslcentro.toscana.it",{"facility":5,"status":82,"city":129,"state":84,"zip":142,"country":86,"countryCode":87,"cosmosGeoPoint":143,"geoPoint":145,"contacts":146},"50134",{"type":89,"coordinates":144},[133,134],{"lat":134,"lon":133},[147,148,149,150],{"name":65,"role":73,"phone":74,"phoneExt":45,"email":75},{"name":69,"role":73,"phone":77,"phoneExt":45,"email":78},{"name":65,"role":67,"phone":45,"phoneExt":45,"email":45},{"name":69,"role":151,"phone":45,"phoneExt":45,"email":45},"SUB_INVESTIGATOR",{"facility":153,"status":82,"city":129,"state":84,"zip":154,"country":86,"countryCode":87,"cosmosGeoPoint":155,"geoPoint":157,"contacts":158},"Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro","50143",{"type":89,"coordinates":156},[133,134],{"lat":134,"lon":133},[159],{"name":160,"role":73,"phone":161,"phoneExt":45,"email":162},"Gianfranco Giannasi, MD","+39 055 69321","gianfranco.giannasi@uslcentro.toscana.it",{"facility":164,"status":82,"city":165,"state":84,"zip":166,"country":86,"countryCode":87,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro","Pescia","51017",{"type":89,"coordinates":168},[169,170],10.68849,43.8871,{"lat":170,"lon":169},[173],{"name":174,"role":73,"phone":175,"phoneExt":45,"email":176},"Gianluca Buffini, MD","+39 0572 4601","gianluca.buffini@uslcentro.toscana.it",{"facility":178,"status":82,"city":179,"state":84,"zip":180,"country":86,"countryCode":87,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Ospedale San Jacopo - Azienda USL Toscana Centro","Pistoia","51100",{"type":89,"coordinates":182},[183,184],10.92365,43.93064,{"lat":184,"lon":183},[187],{"name":188,"role":73,"phone":189,"phoneExt":45,"email":190},"Mirco Donati, MD","+39 0573 3521","mirco.donati@uslcentro.toscana.it",{"facility":192,"status":82,"city":193,"state":84,"zip":194,"country":86,"countryCode":87,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"Ospedale Santo Stefano - Azienda USL Toscana Centro","Prato","59100",{"type":89,"coordinates":196},[197,198],11.09699,43.8805,{"lat":198,"lon":197},[201,202,203],{"name":69,"role":73,"phone":77,"phoneExt":45,"email":78},{"name":45,"role":73,"phone":45,"phoneExt":45,"email":78},{"name":204,"role":67,"phone":45,"phoneExt":45,"email":45},"Simone Magazzini, MD",{"facility":206,"status":82,"city":207,"state":45,"zip":45,"country":86,"countryCode":87,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Ospedale Versilia - Azienda USL Toscana Nord Ovest","Lido di Camaiore",{"type":89,"coordinates":209},[210,211],10.2269,43.90012,{"lat":211,"lon":210},[214,218],{"name":215,"role":73,"phone":216,"phoneExt":45,"email":217},"Gisueppe Pepe, MD","+3905846051","giuseppe.pepe@uslnordovest.toscana.it",{"name":219,"role":67,"phone":45,"phoneExt":45,"email":45},"Giuseppe Pepe, MD",{"facility":221,"status":82,"city":222,"state":45,"zip":223,"country":86,"countryCode":87,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"AORN Antonio Cardarelli","Naples","80131",{"type":89,"coordinates":225},[226,227],14.26811,40.85216,{"lat":227,"lon":226},[230,234],{"name":231,"role":73,"phone":232,"phoneExt":45,"email":233},"Angela Iannuzzi, MD","+390817471111","angela.iannuzzi@aocardarelli.it",{"name":231,"role":67,"phone":45,"phoneExt":45,"email":45},{"facility":236,"status":82,"city":237,"state":45,"zip":238,"country":86,"countryCode":87,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia","Perugia","06129",{"type":89,"coordinates":240},[241,242],12.38878,43.1122,{"lat":242,"lon":241},[245,249],{"name":246,"role":73,"phone":247,"phoneExt":45,"email":248},"Cecilia Becattini, MD, PhD","+390755781","cecilia.becattini@unipg.it",{"name":246,"role":67,"phone":45,"phoneExt":45,"email":45},{"facility":251,"status":82,"city":252,"state":45,"zip":45,"country":86,"countryCode":87,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Azienda Ospedaliero-Universitaria Pisana - Ospedale Cisanello","Pisa",{"type":89,"coordinates":254},[255,256],10.4036,43.70853,{"lat":256,"lon":255},[259,263],{"name":260,"role":73,"phone":261,"phoneExt":45,"email":262},"Lorenzo Ghiadoni, MD, PhD","+39050992111","lorenzo.ghiadoni@unipi.it",{"name":260,"role":67,"phone":45,"phoneExt":45,"email":45},{"facility":265,"status":82,"city":266,"state":45,"zip":267,"country":86,"countryCode":87,"cosmosGeoPoint":268,"geoPoint":272,"contacts":273},"AOU Città della Salute e della Scienza di Torino - Presidio Molinette","Torino","10126",{"type":89,"coordinates":269},[270,271],11.99138,44.88856,{"lat":271,"lon":270},[274,278],{"name":275,"role":73,"phone":276,"phoneExt":45,"email":277},"Fulvio Morello, MD","+390116335555","fulvio.morello@unito.it",{"name":275,"role":67,"phone":45,"phoneExt":45,"email":45},{"facility":280,"status":82,"city":281,"state":45,"zip":45,"country":282,"countryCode":283,"cosmosGeoPoint":284,"geoPoint":288,"contacts":289},"Medical University of Warsaw - Infant Jesus Teaching Hospital","Warsaw","Poland","PL",{"type":89,"coordinates":285},[286,287],21.01178,52.22977,{"lat":287,"lon":286},[290,294],{"name":291,"role":73,"phone":292,"phoneExt":45,"email":293},"Piotr Pruszczyk, MD, PhD","+48225021000","piotr.pruszczyk@wum.edu.pl",{"name":291,"role":67,"phone":45,"phoneExt":45,"email":45},{"facility":296,"status":82,"city":297,"state":45,"zip":45,"country":298,"countryCode":299,"cosmosGeoPoint":300,"geoPoint":304,"contacts":305},"Hospital Universitario Ramón y Cajal","Madrid","Spain","ES",{"type":89,"coordinates":301},[302,303],-3.70256,40.4165,{"lat":303,"lon":302},[306,310],{"name":307,"role":73,"phone":308,"phoneExt":45,"email":309},"David Jiménez, MD, PhD","+34913368000","djimenez.hrc@gmail.com",{"name":307,"role":67,"phone":45,"phoneExt":45,"email":45},{"type":67,"investigatorFullName":312,"investigatorTitle":313,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"Simone Vanni","Director, High Dependency Unit (OSAI); Associate Professor of Internal and Emergency Medicine, University of Florence",[315,317,319,321,324,326,328,330,332],{"name":316,"class":6},"University of Florence",{"name":318,"class":6},"Azienda USL Toscana Centro",{"name":320,"class":6},"Azienda Ospedaliera di Perugia",{"name":322,"class":323},"Cardarelli Hospital, Naples, Italy","UNKNOWN",{"name":325,"class":6},"Azienda Ospedaliero, Universitaria Pisana",{"name":327,"class":6},"Azienda USL Toscana Nord Ovest",{"name":329,"class":6},"Medical University of Warsaw",{"name":331,"class":6},"Hospital Universitario Ramon y Cajal",{"name":333,"class":6},"A.O.U. Città della Salute e della Scienza - Molinette Hospital","100658599","pulmonary-embolism-registry-from-emergency-to-long-term-follow-up-and-surveillance-100658599",false,"NCT07855679","Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance","The PERSEUS Registry - Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance","PERSEUS","Inclusion Criteria:\n\n* Age 18 years or older at the time of presentation.\n* Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:\n* Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;\n* Ventilation\u002Fperfusion (V\u002FQ) lung scintigraphy demonstrating high-probability mismatch;\n* Conventional catheter-directed pulmonary angiography;\n* In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.\n* For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.\n* Written informed consent obtained from the patient or legal surrogate, or waiver\u002Fexception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.\n\nExclusion Criteria:\n\n* Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.","ALL","18 Years",{"count":345,"type":346},5000,"ESTIMATED","5 Years","OBSERVATIONAL","PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.",[351,352,353,354],"Venous Thromboembolism (VTE)","Chronic Thromboembolic Pulmonary Hypertension","Right Ventricular Dysfunction","Pulmonary Embolism (PE)",[356,357,358,353,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379],"Pulmonary Embolism","Acute Pulmonary Embolism","Venous Thromboembolism","Risk Stratification","Prognostic Scores","TELOS-plus","sPESI","Bova Score","ESC Guidelines","AHA\u002FACC Guidelines","High-Sensitivity Troponin","Plasma Lactate","Echocardiography","CT Pulmonary Angiography","Hemodynamic Decompensation","Systemic Thrombolysis","Catheter-Directed Therapy","Observational Registry","Real-World Evidence","Emergency Department","Cardiac Arrest","Prehospital Emergency Care","Point-of-Care Ultrasound","Ambispective Cohort","2026-10-03",{"date":382,"type":383},"2026-10-07","ACTUAL",{"date":385,"type":383},"2026-06-19",{"date":387,"type":346},"2032-07",{"name":5,"class":6},16]